Ibesartan and Health Cost Savings

Published Online: Wednesday, January 1, 2003

According Edmund J. Lewis, MD, director of nephrology at Rush?Presbyterian?St Luke?s Medical Center in Chicago, IL, ?If patients with type 2 diabetes and kidney disease were treated with the angiotensin II receptor blocker irbesartan, we could prevent, in the US alone, about 35,000 cases of end-stage kidney disease at a cost savings of up to $2.3 billion over 3 years.? Dr. Lewis is the lead investigator of the international Irbesartan Diabetic Nephropathy Trial.

By slowing the progression of late-stage kidney disease, irbesartan can put off the need for dialysis or kidney transplant by a year or longer, resulting in a savings of $50,000 per patient per year. The study was funded by an educational grant from Bristol-Myers Squibb and Sanofi-Synthelabo.

Latest Articles
Acute respiratory infections such as the common cold are often accompanied by cough and congestion caused by mucus hypersecretion.
Poor medication adherence is responsible for unnecessary illness, hospitalizations, disability, and premature death, particularly among patients with chronic diseases.
Police and a CVS pharmacy are on the lookout for a man who stole several boxes of diabetic test strips.
The FDA has approved Merck’s supplemental new drug application for single-dose fosaprepitant dimeglumine for injection.
Latest Issues